Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.78 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.70 |
| ▸ | LDHB | P07195 | 4/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL14637227 | 0.90 | KDM1A (0.95) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| Sulfuric Acid SCHEMBL11906224 | 0.90 | KDM1A (0.95) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL49226 | 0.88 | KDM1A (1.00) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL21476977 | 0.88 | KDM1A (1.00) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL31066574 | 0.88 | KDM1A (1.00) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL18902532 | 0.88 | KDM1A (1.00) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| Colistin B SCHEMBL15873840 | 0.88 | KDM1A (0.85) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL14845813 | 0.87 | KDM1A (0.99) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL29394303 | 0.87 | KDM1A (0.99) | KDM1ARCOR1LDHBKEAP1ESR1 | |
| SCHEMBL21474097 | 0.87 | KDM1A (0.99) | KDM1ARCOR1LDHBKEAP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-3568462-B1 | TRANSPORT AND/OR STORAGE MEDIUM FOR MYCOBACTERIUM TUBERCULOSIS | FOND MEDITERRANEE INFECTION (FR) | 2025-07-02 | — | — | EP | claimed |
| EP-4107166-B1 | HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102307-A1 | ACELLULAR BLOOD ALTERNATIVE FOR TRANSFUSION AND ORGAN PERFUSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250361512-A1 | Compositions and Methods Using CPG Oligonucleotides | SIX THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4637788-A1 | COMPOSITIONS AND METHODS OF USING CPG OLIGONUCLEOTIDES | Six Therapeutics Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250319157-A1 | VEGFR FUSION PROTEIN PHARMACEUTICAL COMPOSITION | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2025-10-16 | — | — | US | disclosed |
| EP-3985002-A1 | ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220112542-A1 | SIGNATURE FOR DIAGNOSIS OF BACTERIAL VS VIRAL INFECTIONS | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-04-14 | — | — | US | disclosed |
| EP-3981437-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3978030-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | ModernaTX, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11274345-B2 | Methods for diagnosis of bacterial and viral infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-03-15 | — | — | US | disclosed |
| US-11254908-B2 | Plants containing beneficial endophytes | INDIGO AG, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| EP-3947434-A2 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 Ltd (GB) | 2022-02-09 | — | — | EP | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | KDM1A 4223/4885RCOR1 4011/4885LDHB 262/4885 |
| US-12479856-B2 | Pharmaceutical compounds for the treatment of complement mediated disorders | C5, CFH, C1QBP | KDM1A 4839/4885RCOR1 4765/4885LDHB 1074/4885 |
| US-20260091104-A1 | NUCLEIC ACID VACCINES | RNMT, NSUN2, AMPD1 | KDM1A 1682/4885RCOR1 4837/4885LDHB 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.